Alzhemed & Flurizan

[Guest guest]

Here's what I was referring to:

LAUNCH OF NEUROCHEM'S ALZHEMED AND MYRIAD GENETICS' FLURIZAN WILL BE

PRIMARY DRIVERS IN GROWING DRUG MARKET FOR TREATMENT OF DEMENTIA

Sales of Eisai/Pfizer's Aricept, Novartis's Exelon and

Shire/Janssen's Razadyne Expected to Decline Significantly, According

to a New Report from Decision Resources

October 17, 2005-Waltham, Mass.-Decision Resources, Inc., one of the

world's leading research and advisory firms focusing on

pharmaceutical and health care issues, finds that the launch of

Neurochem's Alzhemed (NC-758) and Myriad Genetics' Flurizan (R-

flurbiprofen) will be the primary drivers in growing the dementia

drug treatment market by 11% annually over the next ten years. The

new Pharmacor report, Strategic Overview of the Dementia Drug Market

2004-2014, forecasts that by 2014 Alzhemed and Flurizan, the first

disease-modifying treatments for dementia, will account for 57% of

drug sales in this market.

Read More:

http://www.decisionresources.com/press_releases/pr_10_17a_2005.htm